News
ARTL
1.325
-1.12%
-0.015
Weekly Report: what happened at ARTL last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at ARTL last week (0408-0412)?
Weekly Report · 04/15 10:52
Weekly Report: what happened at ARTL last week (0401-0405)?
Weekly Report · 04/08 10:57
Artelo Biosciences Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 04/02 15:53
Artelo Biosciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/02 15:53
Weekly Report: what happened at ARTL last week (0325-0329)?
Weekly Report · 04/01 10:54
Artelo Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Artelo Biosciences Inc reported a quarterly adjusted loss of $1.04 per share for the quarter ended in December. The mean expectation of three analysts was for a loss of 56 cents per share. The company's reported revenue was zero; analysts expected zero.
Reuters · 03/29 13:31
Artelo Biosciences Inc <ARTL.OQ> expected to post a loss of $1.06 a share - Earnings Preview
Artelo Biosciences Inc expected to post a loss of $1.06 a share - Earnings Preview. The company is expected to show change in quarterly revenue when it reports results on May 9. LSEG's mean analyst estimate for the company is for a loss.
Reuters · 03/27 12:33
Buy Rating on Artelo Biosciences: Strong Pipeline and Market Potential
TipRanks · 03/26 10:45
Artelo Biosciences Earlier Reported Q4 EPS $(0.99) Misses $(0.56) Estimate
Benzinga · 03/25 20:29
ARTL Stock Earnings: Artelo Biosciences Misses EPS for Q4 2023
Artelo Biosciences reported earnings per share of -99 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -56 cents. Artelo B biosciences just reported results.
Investorplace · 03/25 17:53
Recap: Artelo Biosciences Q4 Earnings
Artelo Biosciences reported its Q4 earnings on March 25. The company missed its earnings estimate by $0.99. The firm is expected to announce its earnings Monday morning. Artelo B biosciences has struggled with sales in the last quarter. The stock is down 7.7% since the start of the quarter.
Benzinga · 03/25 13:20
Artelo Biosciences GAAP EPS of -$3.14 misses by $0.58
Seeking Alpha · 03/25 13:05
Artelo Biosciences FY23 EPS $(3.14) Vs $(3.56) YoY
Cash and investments totalled $10.4 million as of December 31, 2023. Research and development expenses were $5.7 million for the year ended 2023, compared to $4.3 million in 2022. The company reported a net loss of $9.3million for the fiscal 2023 year-end.
Benzinga · 03/25 12:20
*Artelo Biosciences FY23 Loss/Shr $3.14 >ARTL
Dow Jones · 03/25 12:02
*Artelo Biosciences FY23 Research and Development Expenses $5.7M >ARTL
Dow Jones · 03/25 12:02
Press Release: Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
Artelo Biosciences reports financial and operating results for the fiscal year ended December 31, 2023. Major achievements in 2023 lay the foundation for key upcoming milestones. The company is a clinical-stage pharmaceutical company focused on developing treatments for people living with cancer, pain, dermatologic and neurological conditions. Artelo has completed phase 1b of the Cancer Appetite Recovery Study with ART27.13.
Dow Jones · 03/25 12:00
Press Release: Artelo Biosciences Reports Fiscal -2-
This press release. The Company undertakes no obligation to publicly update any forward-looking statement. The Company's shares are trading on the New York Stock Exchange under the symbol "XYZ" Company's stock is expected to rise to $10.
Dow Jones · 03/25 12:00
Weekly Report: what happened at ARTL last week (0318-0322)?
Weekly Report · 03/25 10:57
Artelo Biosciences Has Been Granted European Patent Number EP3723752 Titled "NEW SOLID FORMS OF CANNABIDIOL AND USES THEREOF (FOR VARIOUS MEDICAL TREATMENTS)"
Benzinga · 03/20 16:06
More
Webull provides a variety of real-time ARTL stock news. You can receive the latest news about Artelo Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About ARTL
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. It is developing a dual cannabinoid (CB) agonist that targets both the CB1 and CB2 receptors. This synthetic small molecule program is a G protein-coupled receptor (GPCR) designated ART27.13. ART27.13 is a potential treatment for anorexia associated with cancer. Its second program ART26.12, is a small molecule lead product candidate from its platform of inhibitors of fatty acid binding proteins, notably Fatty Acid Binding Protein 5 (FABP5), which is undergoing pre-clinical research as a potential cancer therapeutic, for pain and inflammation, and in anxiety-related disorders, including post-traumatic stress disorder.